key: cord-0879530-i9ltily6 authors: Arisz, Ryanne A.; Meijer, Piet; Péquériaux, Nathalie C.V.; van de Leur, Sjef J.; Lukens, Michaël V.; de Maat, Moniek P. M.; Hollestelle, Martine J. title: Impact of COVID‐19 pandemic on the quality of test output in haemostasis laboratories date: 2021-11-22 journal: Int J Lab Hematol DOI: 10.1111/ijlh.13760 sha: 6c979d97f3752068e6e30c9093e3291ad8f64818 doc_id: 879530 cord_uid: i9ltily6 INTRODUCTION: The high incidence of thrombotic events in patients with COVID‐19 affects health care worldwide and results in an increased workload in haemostasis laboratories due to more frequent testing of D‐dimer, haemostatic parameters and anti‐Xa tests. However, the impact of this increase in assay requests on the quality of performance in haemostasis laboratories remains unclear. In this study, the impact of the COVID‐19 pandemic on the quality of performance and management of haemostasis laboratories was evaluated. METHODS: The impact on the quality of performance was studied using external quality assessment data from 2019 to 2020 derived from ECAT surveys. A questionnaire was sent to Dutch haemostasis laboratories to identify challenges and management strategies. Furthermore, the number of assays performed in 2019 and 2020 was supplied by four Dutch hospitals, located in regions with different disease incidence. RESULTS: No differences in response rate nor the quality of the measurements were observed between the EQA surveys in 2019 and 2020. The questionnaire results showed a large increase of >25% in the number of test requests for anti‐Xa, D‐dimer and fibrinogen assays in 2020 compared to 2019. Extreme peaks in test requests were also observed in the four evaluated hospitals. Additionally, 84% of the respondents indicated that they had experienced increased work pressure, and increased sick leave was observed in 71% of the participating laboratories. CONCLUSIONS: The enormous increase in test requests, especially for D‐dimer assays and anti‐Xa activity, did not affect the quality of performance within haemostatic laboratories during the COVID‐19 pandemic. disseminated intravascular coagulation and increased prevalence of pulmonary embolisms. [5] [6] [7] [8] [9] Haemostatic parameters, including dramatically increased D-dimer and fibrinogen levels as well as prolonged prothrombin times, were marked as risk factors that indicate a prothrombotic state which is associated with severity of outcome and mortality. 1, 5, 6, [10] [11] [12] [13] [14] Therefore, ISTH guidelines recommend testing D-dimer levels, fibrinogen, platelet count and prothrombin time on admission. 15, 16 Altogether, this has led to an increase of 135% in D-dimer test requests in one particular laboratory. 4 The effect of these changes on the quality of testing performance is not known. Despite treatment with a standard prophylactic dose of low molecular weight heparin (LMWH), approximately 30% of the ICU patients still experienced a thrombotic event, including a venous thromboembolism event or a pulmonary embolism. [6] [7] [8] 15, 17 These observations led to an intensified treatment with LMWH, which involves the use of a double dose of the regular concentration. 8 This treatment regime needs regular monitoring of anti-factor Xa (anti-Xa) levels, which further increases the number of test requests in haemostatic laboratories. The aim of the present study was to evaluate the impact of the COVID-19 pandemic on the quality of test output in haemostasis diagnostic laboratories. The impact on the performance was analysed by comparing relevant data from external quality assessment (EQA) surveys from 2019 to 2020 derived from the EQA programme of the ECAT Foundation. To evaluate the management of haemostasis laboratories, a national questionnaire was sent out to Dutch haemostasis laboratories to identify challenges and differences in management within the laboratories due to the COVID-19 pandemic. This overview may help haemostatic laboratories to gain more knowledge about the quality of test output and performance within different haemostatic laboratories and assist them in improving their strategy in response to changes caused by the COVID-19 pandemic. Survey response rates of ECAT data from both 2019 and 2020 were compared on the basis of various thrombosis and haemostasis parameters. To compare the quality of interlaboratory test output, similar samples were selected, derived from a survey in September/ October 2019, March 2020 and December 2020. For the parameters factor VIII, antithrombin and protein C, a (borderline) normal coagulation control plasma was compared. For UFH and LMWH, a plasma with a level of approximately 0.6 IU/mL and 0.4 IU/mL was selected, respectively. For the APTT, PT and fibrinogen parameters, control plasma from a pool of anticoagulated patients (INR = ~1.7) was used for the comparison. Because the COVID-19 outbreak started in different countries in different periods, it was decided to look only in the Netherlands to find out in detail what effect the COVID-19 pandemic has on the performance of haemostasis laboratories. A web-based questionnaire was designed to evaluate the impact of the pandemic on the Dutch haemostasis laboratories. We evaluated the changes that took place in the logistics of the laboratory, the challenges that were faced with respect to measuring the coagulation parameters and whether the quality performance within the laboratory was compromised. The questionnaire was distributed to all haemostasis laboratories participating in the ECAT programme in the Netherlands. One submission per participating laboratory was allowed. The survey was available from 23 November 2020 to 1 January 2021. Following the questionnaire, we looked in more detail at changes in assay request in four Dutch hospitals, by collecting the number of requested D-dimer, fibrinogen, factor VIII and anti-Xa tests in 2019 and 2020 per month. The data were collected from two peripheral hospitals and two academic hospitals, located in regions with different COVID-19 incidence. In every survey, the interlaboratory coefficient of variation (CV) for methods including more than 10 participants was calculated for all participants worldwide. From these data, an overall mean and standard deviation (SD) of CV per sample and per parameter was calculated. Differences between the surveys were assessed by applying a one-way repeated-measure analysis of variance (ANOVA) using IBM SPSS statistics (version 25). p-Values less than 0.05 were considered to be statistically significant. In an additional calculation, the interlaboratory coefficient of variation was performed for the Dutch laboratories as well. For this smaller group methods were included with more than 5 participants except for D-dimer were the number of participants were 10 or more. Laboratories participated with a similar response rate to the external quality programme during the COVID-19 pandemic as in 2019. A similar response was observed for each of the parameters ( Figure 1 ). The response period was prolonged for 2 to 4 weeks at the start of the COVID-19 pandemic in March 2020 (depending on the survey), but only minimal changes in response rates were seen compared to 2019 ( Figure 1A ,B). The interlaboratory variation at the start of the COVID-19 period (the first survey in March 2020) was of the same order of magnitude for all parameters to that of comparable samples in 2019 (Table 1) . Additionally, comparing a survey at the end of 2020 to the pre-COVID-19 period, also did not show differences in interlaboratory variation (Table 1) . Also in comparison with samples from other surveys in 2019 compared to 2020, we did not find any differences in interlaboratory variation (data not shown). Furthermore, no difference was observed when comparing the interlaboratory variation of Dutch laboratories only (Supplementary table) . The questionnaire focussed on four assays: D-dimer, fibrinogen (Clauss), anti-Xa activity assay and factor VIII activity. Of the 109 invited laboratories, 33 laboratories, who perform at least one of these tests, filled out the complete questionnaire. From these respondents, 97% measured D-dimer levels, 94% fibrinogen levels (Clauss), 61% anti-Xa activity and 39% factor VIII activity. Many laboratories indicated that during the COVID-19 period, they had performed over 25% more anti-Xa activity (57%), D-dimer (55%) and fibrinogen (27%) tests than in the same period before To further illustrate the differences in impact of COVID-19 on laboratories located in regions with a varying COVID-19 incidence, data of D-dimer, anti-Xa activity, fibrinogen and factor VIII activity assays performed were collected from four hospitals, and two peripheral (P) and two academic hospitals (A) located in different regions in the Netherlands with varying disease burden. A strong rise in anti-Xa activity assays was observed in all four hospitals during the first COVID-19 peak (Figure 3 ). However, for other assays, we saw a large variation between hospitals, for example a large increase in D-dimer assays performed was visible in the same period in two hospitals (hospitals 3 (A) and 4 (P)), while this did not occur in the hospitals located more to the north of the Netherlands (hospitals patients, such as remdesivir and dexamethasone, became available during the pandemic, and a higher dose of LMWH was administered to prevent thrombosis, shortening the time that patients hospitalized. [18] [19] [20] [21] In addition to the impact of COVID-19 on the performance of the assays, the impact on the management and the logistics within the laboratories was affected. Over 80% of the responding laboratories reported an increase in the absence of staff due to illness as a result of the COVID-19 pandemic. This increase might have been due to the illness of the personnel but could also have been due to COVID-19 safety rules, which require anyone to stay in quarantine if they have been in contact with a COVID-19 infected person or are suspected of having the COVID-19 infection. 22 Another reason for the higher absence rate might be that the higher workload and extra time-consuming tasks led to an increase in work pressure. While the workload increased for the treatment of COVID-19 patients, regular health care was reduced at the start of the COVID-19 pandemic. 22, 23 This was also seen in the number of factor VIII tests performed, which decreased in April 2020 in two haemophilia treatment centres. This decrease in testing was also observed in other diagnostic laboratories, for example in the pathology field. [24] [25] [26] [27] [28] Thirteen per cent of the respondents to the questionnaire reported that they reduced their test panel to reduce workload. As emphasized in previous literature, the impact on laboratories is an essential aspect that needs to be acknowledged. It was suggested that the daily activity of clinical laboratories may be affected by the large number of tests that have to be performed. 3 Despite the increase in workload, haemostasis laboratories were still able to perform their EQA assessment for all scheduled surveys and no decrease in response rate was observed. Furthermore, the interlaboratory imprecision did not change after the COVID-19 pandemic started. This means that overall, the laboratories were able to preserve the quality of testing, despite all changes in test requests and logistic changes. The results of the questionnaire among Dutch haemostasis laboratories also confirmed that the COVID-19 epidemic did not affect the quality of tests performed. The strength of this study is that the EQA data were derived from international haemostasis laboratories participating in the ECAT programme. A limitation is that evaluation of other effects such as the quantity performance of assays and logistical changes was limited to Dutch laboratories. Furthermore, only the overall changes in quality of test output are studied, and individual laboratory data are not compared. In conclusion, the quality of testing performance of haemostasis laboratories internationally has not been affected by the impact of the COVID-19 pandemic, despite the increased workload. This increase in workload was caused by a major increase in work pressure and test requests, especially for D-dimer assays and anti-Xa activity tests, as observed in Dutch haemostasis laboratories. Distribution of the COVID-19 epidemic and correlation with population emigration from Wuhan. China COVID-19) dashboard. Geneva: World Health Organization The critical role of laboratory medicine during coronavirus disease 2019 (COVID-19) and other viral outbreaks Adaptation of Clinical Laboratories to COVID 19 Pandemic: Changes in Test Panels, Overcoming Problems and Preparation Suggestions for Future Pandemics Adaptation of Clinical Laboratories to COVID 19 Pandemic Coagulation biomarkers are independent predictors of increased oxygen requirements in COVID-19 High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study Incidence of thrombotic complications in critically ill ICU patients with COVID-19 Incidence of venous thromboembolism in hospitalized patients with COVID-19 Incidence of Venous Thromboembolism and Mortality in Patients with Initial Presentation of COVID-19 Covid-19: The Rollercoaster of Fibrin(Ogen), D-Dimer, Von Willebrand Factor, P-Selectin and Their Interactions with Endothelial Cells Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan. China Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan. China Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia ISTH interim guidance on recognition and management of coagulopathy in COVID-19 Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19 Remdesivir for the Treatment of Covid-19 -Final Report Incidence of thrombotic complications and overall survival in hospitalized patients with COVID-19 in the second and first wave Global impact of the COVID-19 pandemic on cytopathology practice: Results from an international survey of laboratories in 23 countries Impact of the coronavirus disease 2019 pandemic on cancer treatment: the patients' perspective Global Impact of COVID-19 on Nuclear Medicine Departments: An International Survey in April 2020 The impact of the temporary suspension of national cancer screening programmes due to the COVID-19 epidemic on the diagnosis of breast and colorectal cancer in the Netherlands The Impact of the COVID-19 Pandemic and the Associated Belgian Governmental Measures on Cancer Screening The authors thank all the participating laboratories who responded to our questionnaire. Also, we would like to acknowledge D. Priem-Visser for her contribution in data collection for this paper. Additional supporting information may be found in the online version of the article at the publisher's website.